Pfizer (PFE) to Acquire Arena Pharmaceuticals (ARNA) for $100 Per Share, $6.7 Billion Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nvidia's revenue forecast lifts Wall Street; investors eye the Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst
December 13, 2021 9:30 AM ESTEarlier today, Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately... More
Low Valuations to Drive Pharma M&A in 2022 - Analyst
December 13, 2021 8:50 AM ESTIn light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More
